The Elizabeth Glaser Pediatric AIDS Foundation proposes to present the results of the New Horizons Study, a four-year study which explored data from a cohort of over 800 of children, adolescents and young adults (ages 0-24 years) who ever received Darunavir (DRV) and/or Etravirine (ETR) as part of second- or third-line antiretroviral therapy in 9 African countries: Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe. An overview of patient characteristics, prevalence of drug resistance mutations, and viral suppression after initiation on DRV and/or ETR will be shared, along with case studies highlighting different national models for improving the care of highly treatment-experienced young people. A panel of experts will lead a discussion on how to detect treatment failure, sequence ART regimens, and the next steps needed to improve the quality of life for these priority populations.